Cargando…

PROTAC technology as a novel tool to identify the target of lathyrane diterpenoids

Detalles Bibliográficos
Autores principales:	Wu, Yanli, Yang, Yueying, Wang, Wang, Sun, Dejuan, Liang, Jing, Zhu, Man, Li, Hua, Chen, Lixia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643283/ https://www.ncbi.nlm.nih.gov/pubmed/36386476 http://dx.doi.org/10.1016/j.apsb.2022.07.007

Ejemplares similares

Pharmacological Potential of Lathyrane-Type Diterpenoids from Phytochemical Sources
por: Vela, Fátima, et al.
Publicado: (2022)

Two lathyrane diterpenoid stereoisomers containing an unusual trans-gem-dimethylcyclopropane from the seeds of Euphorbia lathyris
por: Li, Linwei, et al.
Publicado: (2021)

A Cytochrome P450‐Mediated Intramolecular Carbon–Carbon Ring Closure in the Biosynthesis of Multidrug‐Resistance‐Reversing Lathyrane Diterpenoids
por: King, Andrew J., et al.
Publicado: (2016)

Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action
por: Liu, Qian, et al.
Publicado: (2020)

FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
por: Gao, Hongying, et al.
Publicado: (2020)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

Developing potent PROTACs tools for selective degradation of HDAC6 protein
por: An, Zixuan, et al.
Publicado: (2019)

In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15
por: Li, Liang, et al.
Publicado: (2020)

PROTACs– a game-changing technology
por: Konstantinidou, Markella, et al.
Publicado: (2019)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Synthetic study toward the diterpenoid aberrarone
por: Shi, Liang, et al.
Publicado: (2022)

Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021)

Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC
por: Kong, Lingping, et al.
Publicado: (2023)

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022)

Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
por: Lospinoso Severini, Ludovica, et al.
Publicado: (2022)

Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
por: Pei, Haixiang, et al.
Publicado: (2019)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Recent Advances of Degradation Technologies Based on PROTAC Mechanism
por: Xiao, Mingchao, et al.
Publicado: (2022)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
por: Wang, Chao, et al.
Publicado: (2022)

BRD4-targeting PROTAC as a unique tool to study biomolecular condensates
por: Shi, Yi, et al.
Publicado: (2023)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
por: Burke, Matthew R., et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
por: Shao, Jingwei, et al.
Publicado: (2021)

Recent Advances in PROTACs for Drug Targeted Protein Research
por: Yao, Tingting, et al.
Publicado: (2022)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

PROTAC targeted protein degraders: the past is prologue
por: Békés, Miklós, et al.
Publicado: (2022)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

PROTAC: targeted drug strategy. Principles and limitations
por: Koroleva, O. A., et al.
Publicado: (2022)

Editorial: PROTACs: Targeted therapies for cancer treatment
por: Tabassum, Sobia
Publicado: (2023)

Editorial: PROTACs: Targeted therapies for cancer treatment
por: Tabassum, Sobia
Publicado: (2023)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
por: Moon, Yujeong, et al.
Publicado: (2023)

Marine diterpenoid targets STING palmitoylation in mammalian cells
por: Hsiao, Wan-Chi, et al.
Publicado: (2023)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
por: Poso, Antti
Publicado: (2021)

BacPROTACs mediate targeted protein degradation in bacteria
por: Morreale, Francesca E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i565bcii541o227tqgen56m1on